These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

812 related items for PubMed ID: 27002108

  • 1. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
    Conaghan PG, Østergaard M, Bowes MA, Wu C, Fuerst T, van der Heijde D, Irazoque-Palazuelos F, Soto-Raices O, Hrycaj P, Xie Z, Zhang R, Wyman BT, Bradley JD, Soma K, Wilkinson B.
    Ann Rheum Dis; 2016 Jun; 75(6):1024-33. PubMed ID: 27002108
    [Abstract] [Full Text] [Related]

  • 2. Very early MRI responses to therapy as a predictor of later radiographic progression in early rheumatoid arthritis.
    Conaghan PG, Østergaard M, Troum O, Bowes MA, Guillard G, Wilkinson B, Xie Z, Andrews J, Stein A, Chapman D, Koenig A.
    Arthritis Res Ther; 2019 Oct 21; 21(1):214. PubMed ID: 31639034
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
    Fleischmann R, Mease PJ, Schwartzman S, Hwang LJ, Soma K, Connell CA, Takiya L, Bananis E.
    Clin Rheumatol; 2017 Jan 21; 36(1):15-24. PubMed ID: 27734232
    [Abstract] [Full Text] [Related]

  • 4. Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: a magnetic resonance imaging study of 318 methotrexate-naive rheumatoid arthritis patients.
    Østergaard M, Emery P, Conaghan PG, Fleischmann R, Hsia EC, Xu W, Rahman MU.
    Arthritis Rheum; 2011 Dec 21; 63(12):3712-22. PubMed ID: 22127693
    [Abstract] [Full Text] [Related]

  • 5. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study.
    van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzová D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA, ORAL Scan Investigators.
    Arthritis Rheum; 2013 Mar 21; 65(3):559-70. PubMed ID: 23348607
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C, van der Heijde D, Burmester GR, Nash P, Zerbini CAF, Connell CA, Fan H, Kwok K, Bananis E, Fleischmann R.
    J Rheumatol; 2018 Feb 21; 45(2):177-187. PubMed ID: 29142036
    [Abstract] [Full Text] [Related]

  • 10. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA).
    Hetland ML, Ejbjerg B, Hørslev-Petersen K, Jacobsen S, Vestergaard A, Jurik AG, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, Tarp U, Skjødt H, Pedersen JK, Majgaard O, Svendsen AJ, Ellingsen T, Lindegaard H, Christensen AF, Vallø J, Torfing T, Narvestad E, Thomsen HS, Ostergaard M, CIMESTRA study group.
    Ann Rheum Dis; 2009 Mar 21; 68(3):384-90. PubMed ID: 18388160
    [Abstract] [Full Text] [Related]

  • 11. Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.
    Strand V, Mysler E, Moots RJ, Wallenstein GV, DeMasi R, Gruben D, Soma K, Iikuni N, Smolen JS, Fleischmann R.
    RMD Open; 2019 Mar 21; 5(2):e001040. PubMed ID: 31673419
    [Abstract] [Full Text] [Related]

  • 12. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
    Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Gruben D, Wallenstein G, Krishnaswami S, Zwillich SH, Koncz T, Soma K, Bradley J, Mebus C, ORAL Step investigators.
    Lancet; 2013 Feb 09; 381(9865):451-60. PubMed ID: 23294500
    [Abstract] [Full Text] [Related]

  • 13. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
    Yamanaka H, Tanaka Y, Takeuchi T, Sugiyama N, Yuasa H, Toyoizumi S, Morishima Y, Hirose T, Zwillich S.
    Arthritis Res Ther; 2016 Jan 28; 18():34. PubMed ID: 26818974
    [Abstract] [Full Text] [Related]

  • 14. Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.
    Conaghan PG, Durez P, Alten RE, Burmester GR, Tak PP, Klareskog L, Catrina AI, DiCarlo J, Gaillez C, Le Bars M, Zhou X, Peterfy C.
    Ann Rheum Dis; 2013 Aug 28; 72(8):1287-94. PubMed ID: 22915624
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis.
    Strand V, van Vollenhoven RF, Lee EB, Fleischmann R, Zwillich SH, Gruben D, Koncz T, Wilkinson B, Wallenstein G.
    Rheumatology (Oxford); 2016 Jun 28; 55(6):1031-41. PubMed ID: 26929445
    [Abstract] [Full Text] [Related]

  • 19. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.
    Axelsen MB, Eshed I, Hørslev-Petersen K, Stengaard-Pedersen K, Hetland ML, Møller J, Junker P, Pødenphant J, Schlemmer A, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Krogh NS, Johansen JS, Østergaard M, OPERA study group.
    Ann Rheum Dis; 2015 May 28; 74(5):867-75. PubMed ID: 24412895
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 41.